Seeking Alpha

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its...

Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its treatment therapy for patients with severely calcified coronary lesions had exceeded expectations by a significant margin. The study is reviewing the safety and effectiveness of it's orbital atherectomy technology and is the first Investigational Device Exemption study to seek approval for treating these lesions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs